8-K filed Nov 9, 2026 at 07:30 ET
Inovio Pharmaceuticals filed an 8-K reporting the entry into an underwriting agreement for a $75M public offering of 58.7M common shares and pre-funded warrants for 12.7M shares, with the underwriters exercising their option to purchase an additional 10.7M shares in full. Net proceeds are expected to be approximately $80.5M, which management believes will fund operations into late Q4 2027. The offering follows the recent FDA accelerated approval of VOCERYQ and comes just days after a prior 424B5 filing for the same $75M raise, confirming acute capital needs at a $150M market cap with massive dilution.